|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Shen YC, Hsu C and Cheng AL: Molecular
targeted therapy for advanced hepatocellular carcinoma: current
status and future perspectives. J Gastroenterol. 45:794–807. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Asghar U and Meyer T: Are there
opportunities for chemotherapy in the treatment of hepatocellular
cancer? J Hepatol. 56:686–695. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen KF, Chen HL, Tai WT, et al:
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway
mediates acquired resistance to sorafenib in hepatocellular
carcinoma cells. J Pharmacol Exp Ther. 337:155–161. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Courtney KD, Corcoran RB and Engelman JA:
The PI3K pathway as drug target in human cancer. J Clin Oncol.
28:1075–1083. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen TA, Wang JL, Hung SW, Chu CL, Cheng
YC and Liang SM: Recombinant VP1, an Akt inhibitor, suppresses
progression of hepatocellular carcinoma by inducing apoptosis and
modulation of CCL2 production. PLoS One. 6:e233172011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Masuda M, Shimomura M, Kobayashi K, Kojima
S and Nakatsura T: Growth inhibition by NVP-BEZ235, a dual
PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines. Oncol
Rep. 26:1273–1279. 2011.PubMed/NCBI
|
|
8
|
Jung KH, Choi MJ, Hong S, et al: HS-116, a
novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and
suppresses angiogenesis of hepatocellular carcinoma through
inhibition of the PI3K/AKT/mTOR pathway. Cancer Lett. 316:187–195.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dan S, Yoshimi H, Okamura M, Mukai Y and
Yamori T: Inhibition of PI3K by ZSTK474 suppressed tumor growth not
via apoptosis but G0/G1 arrest. Biochem Biophys Res Commun.
379:104–109. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang H, Fan D, Zhou G, Li X and Deng H:
Phosphatidylinositol 3-kinase inhibitor (LY294002) induces
apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J
Exp Clin Cancer Res. 29:342010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Faber AC, Li D, Song Y, et al:
Differential induction of apoptosis in HER2 and EGFR addicted
cancers following PI3K inhibition. Proc Natl Acad Sci USA.
106:19503–19508. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Donev IS, Wang W, Yamada T, Li Q, Takeuchi
S, Matsumoto K, Yamori T, Nishioka Y, Sone S and Yano S: Transient
PI3K inhibition induces apoptosis and overcomes HGF-mediated
resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer
Res. 17:2260–2269. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cokakli M, Erdal E, Nart D, et al:
Differential expression of Caveolin-1 in hepatocellular carcinoma:
correlation with differentiation state, motility and invasion. BMC
Cancer. 9:652009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Aksamitiene E, Kiyatkin A and Kholodenko
BN: Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt
pathways: a fine balance. Biochem Soc Trans. 40:139–146. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hallstrom TC and Nevins JR: Balancing the
decision of cell proliferation and cell fate. Cell Cycle.
8:532–535. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mínguez B, Tovar V, Chiang D, Villanueva A
and Llovet JM: Pathogenesis of hepatocellular carcinoma and
molecular therapies. Curr Opin Gastroenterol. 25:186–194.
2009.PubMed/NCBI
|
|
17
|
Karakas B, Bachman KE and Park BH:
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer.
94:455–459. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li W, Tan D, Zhang Z, Liang JJ and Brown
RE: Activation of Akt-mTOR-p70S6K pathway in angiogenesis in
hepatocellular carcinoma. Oncol Rep. 20:713–719. 2008.PubMed/NCBI
|
|
19
|
Schmitz KJ, Wohlschlaeger J, Lang H, et
al: Activation of the ERK and AKT signalling pathway predicts poor
prognosis in hepatocellular carcinoma and ERK activation in cancer
tissue is associated with hepatitis C virus infection. J Hepatol.
48:83–90. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakanishi K, Sakamoto M, Yamasaki S, Todo
S and Hirohashi S: Akt phosphorylation is a risk factor for early
disease recurrence and poor prognosis in hepatocellular carcinoma.
Cancer. 103:307–312. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Semba S, Itoh N, Ito M, Harada M and
Yamakawa M: The in vitro and in vivo effects of
2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific
inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer
cells. Clin Cancer Res. 8:1957–1963. 2002.
|
|
22
|
Bondar VM, Sweeney-Gotsch B, Andreeff M,
Mills GB and McConkey DJ: Inhibition of the phosphatidylinositol
3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma
cells in vitro and in vivo. Mol Cancer Ther.
1:989–997. 2002.
|
|
23
|
Lin J, Adam RM, Santiestevan E and Freeman
MR: The phosphatidylinositol 3′-kinase pathway is a dominant growth
factor-activated cell survival pathway in LNCaP human prostate
carcinoma cells. Cancer Res. 59:2891–2897. 1999.
|
|
24
|
Engelman JA, Chen L, Tan X, et al:
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D
and PIK3CA H1047R murine lung cancers. Nat Med. 14:1351–1356. 2008.
View Article : Google Scholar : PubMed/NCBI
|
